Redefine the patient journey with an intuitive, powerful combination of next-generation sequencing (NGS) and pharmacogenomics testing (PGx) — a new approach that AccessDX research shows helps enhance and extend patient lives.
No two tumors are alike. No two patients are alike.
Many oncologists use NGS alone to support therapy decisions. However, oncologists can maximize cancer therapy by using NGS to evaluate the patient’s tumor, while PGx establishes a clear understanding of the patient’s potential drug/gene and drug/drug interactions to determine effective dose.
Oncologists often introduce genomic tests in the later stages of cancer. However, by introducing next-generation sequencing and pharmacogenomics testing early in the patient’s journey, AccessDX insights show that it can help enhance and extend a patient’s life.
Introducing genomic tests at the beginning stages enables physicians to be proactive and predictive in a patient’s cancer treatment.
We go beyond the report. Following the initial diagnostics and reports, our staff continuously discusses the clinical implications, giving proactive, predictive recommendations to help physicians improve diagnosis and optimize therapy decisions. AccessDX also offers continual monitoring services and provides information on whether drug dosage adjustment is needed. Our PharmD call center is available to all physicians.